|
Exercise Training in Patients With Persistent or Permanent Atrial Fibrillation
RECRUITINGN/ASponsored by Ottawa Heart Institute Research Corporation
Actively Recruiting
PhaseN/A
SponsorOttawa Heart Institute Research Corporation
Started2019-01-23
Est. completion2024-12-30
Eligibility
Age40 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT03397602
Summary
The main purpose of this project is to evaluate the effects of high-intensity interval training (HIIT) compared to moderate-intensity continuous exercise training (MICE) and standard care on exercise capacity and quality of life in patients with persistent or permanent atrial fibrillation. Positive findings are vitally important for these patients, given the condition's substantial morbidity, mortality and high economic costs.
Eligibility
Age: 40 Years+Healthy volunteers accepted
Inclusion Criteria: 1. persistent or permanent atrial fibrillation; 2. rate controlled with a resting ventricular rate of equal to or less than 100 bpm; 3. able to perform a symptom-limited exercise test; 4. at least 40 years of age (i.e. participants must be 40 years or older); Exclusion Criteria: 1. currently participating in routine exercise training (more than two times per week); 2. unstable angina; 3. diagnosed severe mitral or aortic stenosis; 4. diagnosed hypertrophic obstructive cardiomyopathy with significant obstruction; 5. pregnant, lactating or planning to become pregnant during the study period; 6. unable to provide written, informed consent, or 7. unwilling or unable to return for follow up at week 12.
Conditions2
Atrial FibrillationHeart Disease
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhaseN/A
SponsorOttawa Heart Institute Research Corporation
Started2019-01-23
Est. completion2024-12-30
Eligibility
Age40 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT03397602